Skip to main content

Drug Interactions between doravirine and Mycobutin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

rifabutin doravirine

Applies to: Mycobutin (rifabutin) and doravirine

ADJUST DOSE: Coadministration with rifabutin may significantly decrease the plasma concentrations of doravirine. The mechanism is rifabutin induction of doravirine metabolism via CYP450 3A4. When a single 100 mg dose of doravirine was administered with rifabutin 300 mg once daily in 12 study subjects, doravirine peak plasma concentration (Cmax) did not change, but systemic exposure (AUC) and trough plasma concentration (C24hr) decreased by an average of 50% and 68%, respectively, compared to doravirine administered alone. Reduced efficacy of doravirine may occur.

MANAGEMENT: When used with rifabutin, doravirine dosage should be increased to 100 mg twice daily (approximately 12 hours apart) for the duration of rifabutin coadministration. Otherwise, doravirine should not be initiated until at least 4 weeks after cessation of rifabutin.

References (1)
  1. (2018) "Product Information. Pifeltro (doravirine)." Merck & Co., Inc

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer